Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash & Current Investments (2020 - 2025)

Ovid Therapeutics' Cash & Current Investments history spans 6 years, with the latest figure at $69.6 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 32.5% year-over-year to $69.6 million; the TTM value through Dec 2025 reached $69.6 million, up 32.5%, while the annual FY2025 figure was $69.6 million, 32.5% up from the prior year.
  • Cash & Current Investments reached $69.6 million in Q4 2025 per OVID's latest filing, up from $25.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $233.1 million in Q1 2021 to a low of $25.6 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $113.6 million, with a median of $100.7 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 414.29% in 2021, then plummeted 59.61% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $187.8 million in 2021, then crashed by 32.83% to $126.1 million in 2022, then fell by 16.1% to $105.8 million in 2023, then plummeted by 50.34% to $52.6 million in 2024, then soared by 32.5% to $69.6 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Cash & Current Investments are $69.6 million (Q4 2025), $25.6 million (Q3 2025), and $30.7 million (Q2 2025).